| Literature DB >> 22964497 |
Soek Sin Teh1, Gwendoline Cheng Lian Ee, Siau Hui Mah, Yang Mooi Lim, Mawardi Rahmani.
Abstract
An investigation on biologically active secondary metabolites from the stem bark of Mesua beccariana was carried out. A new cyclodione, mesuadione, along with several known constituents which are beccamarin, 2,5-dihydroxy-1,3,4-trimethoxy anthraquinone, 4-methoxy-1,3,5-trihydroxyanthraquinone, betulinic acid and stigmasterol were obtained from this ongoing research. Structures of these compounds were elucidated by extensive spectroscopic methods, including 1D and 2D-NMR, GC-MS, IR and UV techniques. Preliminary tests of the in vitro cytotoxic activities of all the isolated metabolites against a panel of human cancer cell lines Raji (lymphoma), SNU-1 (gastric carcinoma), K562 (erythroleukemia cells), LS-174T (colorectal adenocarcinoma), HeLa (cervical cells), SK-MEL-28 (malignant melanoma cells), NCI-H23 (lung adenocarcinoma), IMR-32 (neuroblastoma) and Hep-G2 (hepatocellular liver carcinoma) were carried out using an MTT assay. Mesuadione, beccamarin, betulinic acid and stigmasterol displayed strong inhibition of Raji cell proliferation, while the proliferation rate of SK-MEL-28 and HeLa were strongly inhibited by stigmasterol and beccamarin, indicating these secondary metabolites could be anti-cancer lead compounds in drug discovery.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22964497 PMCID: PMC6268802 DOI: 10.3390/molecules170910791
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds.
1H-NMR (400 MHz, CDCl3) and 13C-NMR (100 MHz, CDCl3) data for compound 1.
| Position | 1H ( | 13C ( | HMBC |
|---|---|---|---|
| 1 | − | − | − |
| 2 | − | 174.1 | − |
| 3 | 2.29 ( | 35.0 | C-2, C-4, C-5 |
| 4 | 1.61 ( | 25.4 | C-2, C-3, C-5, C-6 |
| 5 | 1.61 ( | 29.2 | C-3, C-6 |
| 6 | 4.08 ( | 64.3 | C-5, C-8 |
| 7 | − | − | − |
| 8 | − | 174.1 | − |
| 9 | 2.29 ( | 35.0 | C-8 |
| 10 | 2.03 ( | 28.0 | C-11, C-12 |
| 11 | 5.29 ( | 130.3 | C-9, C-10 |
| 12 | 5.29 ( | 130.2 | C-10 |
| 13 | 5.29 ( | 130.2 | − |
| 14 | 5.29 ( | 130.3 | C-16 |
| 15 | 2.03 ( | 26.4 | C-13, C-14, C-17 |
| 16 | 1.39 ( | 27.2 | C-14, C-17, C-18 |
| 17 | 1.61 ( | 29.3 | C-15, C-18 |
| 18 | 4.08 ( | 64.3 | C-2, C-17 |
Figure 2HMBC correlations in 1.
IC50 values of a Panel of Human Cancer Cell Lines Treated with Compounds 1–6 and standards.
| Compounds | Cell lines with IC50 values (μg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Raji | SNU-1 | K562 | LS-174T | SK-MEL-28 | IMR 32 | HeLa | Hep G2 | NCI-H23 | |
| Mesuadione ( | 4.58 | 15.62 | 8.60 | 40.00 | 21.87 | 10.62 | 20.83 | 21.80 | 10.42 |
| Beccamarin ( | 2.92 | 16.56 | − | 40.00 | − | − | 3.91 | 43.75 | 20.31 |
| 2,5-Dihydroxy-1,3,4-trimethoxyanthraquinone ( | − | − | − | − | − | − | 9.30 | − | − |
| Betulinic acid ( | 4.16 | 7.30 | − | − | − | − | 23.44 | − | − |
| Stigmasterol ( | 0.17 | − | − | − | 3.90 | − | − | − | − |
| Kaempferol | 12.5 | 10.93 | − | − | 21.87 | − | 5.00 | 33.33 | 18.75 |
| Quercetin | 2.08 | 6.30 | 9.89 | − | 21.88 | 31.25 | 8.00 | 5.21 | 17.50 |
Note: IC50 more than 50 µg/mL indicates weak activity and is indicated by −. Each data point represents the mean of the three independent experiments (significant differences at p < 0.05).
Figure 3Cytotoxicity of Compounds 1–6 towards (i), (ii), (iii) Raji; (iv) SNU-1; (v) K562 and (vi) LS174T Cells. Bars denote statically significant differences at p < 0.05. Each data point represents the mean ± SD of three independent experiments.
Figure 4Cytotoxicity of Compounds 1–6 towards (i), (ii) SK-MEL-28, (iii) IMR-32; (iv) HeLa; (v) HEP G2 and (vi) NCI-H23 Cells. Bars denote statically significant differences at p < 0.05. Each data point represents the mean ± SD of three independent experiments.